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Abstract
The effects of retinoids, the structural derivatives of vitamin A (retinol), on post-natal peak bone density acquisition and
skeletal remodeling are complex and compartment specific. Emerging data indicates that retinoids, such as all trans retinoic
acid (ATRA) and its precursor all trans retinaldehyde (Rald), exhibit distinct and divergent transcriptional effects in
metabolism. Despite these observations, the role of enzymes that control retinoid metabolism in bone remains undefined.
In this study, we examined the skeletal phenotype of mice deficient in retinaldehyde dehydrogenase 1 (Aldh1a1), the
enzyme responsible for converting Rald to ATRA in adult animals. Bone densitometry and micro-computed tomography
(mCT) demonstrated that Aldh1a1-deficient (Aldh1a1
2/2) female mice had higher trabecular and cortical bone mass
compared to age and sex-matched control C57Bl/6 wild type (WT) mice at multiple time points. Histomorphometry
confirmed increased cortical bone thickness and demonstrated significantly higher bone marrow adiposity in Aldh1a1
2/2
mice. In serum assays, Aldh1a1
2/2 mice also had higher serum IGF-1 levels. In vitro, primary Aldh1a1
2/2 mesenchymal stem
cells (MSCs) expressed significantly higher levels of bone morphogenetic protein 2 (BMP2) and demonstrated enhanced
osteoblastogenesis and adipogenesis versus WT MSCs. BMP2 was also expressed at higher levels in the femurs and tibias of
Aldh1a1
2/2 mice with accompanying induction of BMP2-regulated responses, including expression of Runx2 and alkaline
phosphatase, and Smad phosphorylation. In vitro, Rald, which accumulates in Aldh1a1
2/2 mice, potently induced BMP2 in
WT MSCs in a retinoic acid receptor (RAR)-dependent manner, suggesting that Rald is involved in the BMP2 increases seen
in Aldh1a1 deficiency in vivo. Collectively, these data implicate Aldh1a1 as a novel determinant of cortical bone density and
marrow adiposity in the skeleton in vivo through modulation of BMP signaling.
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Introduction
Retinoids - the products of retinol (vitamin A) and b carotene
metabolism - direct fundamental cellular processes and play a
crucial role in limb patterning and skeletal development [1].
Several lines of evidence indicate that retinoids also influence
endochondral bone beyond development; however, the molecular
basis of post-natal retinoid actions in bone remains poorly
understood. Early pre-clinical studies in rodent models linked
hypervitaminosis A with skeletal abnormalities and increased bone
fragility [2], while human epidemiological studies identify high
retinol intake as a risk factor for hip fractures in the elderly [3,4].
Animal studies demonstrate that retinol and its main metabolite all
trans retinoic acid (ATRA) consistently increase bone fragility in
rodent models by reducing radial bone growth and bone density
[5–8]. In vitro studies of retinoid regulation in bone cells have
yielded more conflicting results. Retinoids have been reported to
either induce or inhibit in vitro osteoblastogenesis and osteoclasto-
genesis depending on the differentiation marker examined and the
cell system employed [9–16].
A recent study demonstrated that ATRA may also modulate
fundamental cell fate decisions in the marrow niche. ATRA
exerted divergent effects on osteoblastogenesis and adipogenesis in
mesenchymal stem cells (MSCs), the common progenitor of
marrow osteoblasts and adipocytes [17]. While ATRA induced the
osteoblast marker alkaline phosphatase (ALP), it blocked adipo-
genesis in CH310T1/2 MSCs through a bone morphogenetic
protein 2 (BMP2)-dependent pathway. Furthermore, the opposing
effects of ATRA on osteoblastogenesis and adipogenesis in MSCs
appear to depend on ATRA-mediated induction of Smad3
[18,19], a downstream transcriptional mediator of BMP signaling
pathways. BMP2, a member of the transforming growth factor
(TGF)- b superfamily of cytokines, acts in a paracrine and
autocrine manner to promote MSC osteoblastogenesis and
enhance the osteogenic activity of differentiated osteoblasts
[20,21]. Interestingly, beyond its essential role in bone formation,
BMP2 also promotes adipogenesis in CH310T1/2 mesenchymal
cells [22–24].
Multiple structurally distinct retinoids exist that exert divergent
biologic effects. As such, a complex system of metabolizing
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e71307enzymes and transport proteins governs retinoid generation and
free levels in a precise, controlled manner [25,26]. Retinol is
inactive and must be metabolized in order to exert its pleotropic
actions. Retinol is first converted to all trans retinaldehyde (Rald)
by alcohol dehydrogenases (ADHs). Subsequently, Rald is
converted to ATRA, the main structural derivative of retinol,
through the action of retinaldehyde dehydrogenase 1 (Aldh1)
isoforms. While Aldh1a2 and Aldh1a3 control fundamental
aspects of retinoid metabolism during embryonic development,
Aldh1a1 is the main enzyme responsible for converting Rald to
ATRA in adult animals and is the only isoform whose deficiency is
not embryonically lethal [27].
Given Aldh1a1’s role as the rate-limiting enzyme in the
biogenesis of ATRA in vivo, we hypothesized Aldh1a1 functions
as a potentially novel determinant of fundamental aspects of
skeletal remodeling and bone metabolism. To investigate this, we
performed skeletal phenotyping of Aldh1a1-deficient (Aldh1a1
2/2)
mice and examined the effect of Aldh1a1 deficiency on MSC
differentiation. We demonstrate here that female Aldh1a1
2/2 mice
have higher cortical bone density and greater marrow adiposity
when compared to age and sex matched wild type controls (WT).
In exploring mechanisms underlying this coordinated change in
bone density and marrow adiposity, we found primary Aldh1a1
2/2
MSCs express higher levels of BMP2 and demonstrate enhanced
osteoblastogenesis and adipogenesis in vitro. In addition, Aldh1a1
2/
2 mice express higher levels of BMP2 and its downstream targets
such as runt-related transcription factor 2 (Runx2) and alkaline
phosphatase (ALP) in their femurs and tibias compared to WT
controls. In keeping with these effects, stimulation of WT MSCs
with Rald, which accumulates in vivo in Aldh1a1
2/2 mice, induced
BMP2 expression in a retinoic acid receptor (RAR)-dependent
manner. Taken together, these data identify Aldh1a1 as a novel
determinant of cortical bone formation through it’s action on
BMP2.
Materials and Methods
Mice
Aldh1a1
2/2 mice and C57BL/6 mice were housed at Harvard
Medical School. The Aldh1a1
2/2 mice were originally generated
on a C57BL/6 background and provided by Dr. Gregg Duester,
Burnham Institute, La Jolla, CA [28]. Developmental phenotyping
studies were carried out on age and sex-matched female wild type
control (WT) and Aldh1a1
2/2 mice that were maintained at 25uC
on a 12-hour light-dark cycle on standard chow diet (10.6% kcal
fat PicoLab 20 Rodent diet 5506, Vitamin A content of 15 IU/g
of diet).
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Harvard Medical School Institu-
tional Animal Care and Use Committee (Protocol 03998). Bones
and tissues were harvested after euthanasia by Harvard IACUC-
approved CO2 inhalation protocols and all efforts were made to
minimize suffering.
Dual-energy x-ray Absorptiometry (DXA)
Dual-energy x-ray absorptiometry (DXA) scanning was per-
formed using the PIXImus system (GE-Lunar, Madison, WI) as
previously described [29]. The PIXImus was used to assess
femoral bone mineral density (BMD), and bone mineral content
(BMC) in WT and Aldh1a1
2/2 mice at multiple developmental
time points including 8 weeks (WT n=5, Aldh1a1
2/2 n=5), 12
weeks (WT n=20, Aldh1a1
2/2 n=18), 18 weeks (WT n=10,
Aldh1a1
2/2 n=10), 26 weeks (WT n=10, Aldh1a1
2/2 n=9), and
36 weeks (WT n=4, Aldh1a1
2/2 n=4). A phantom standard
provided by the manufacturer was assessed each day for
instrument calibration.
Micro-computed Tomography (mCT)
Microarchitecture of the trabecular bone and midshaft cortical
bone of the femur was analyzed by mCT (resolution 10 mm,
VivaCT-40; Scanco Medical AG, Bassersdorf, Switzerland) at
multiple developmental time points including 6 weeks (WT n=5,
Aldh1a1
2/2 n=5), 8 weeks (WT n=5, Aldh1a1
2/2 n=5), 12
weeks (WT n=20, Aldh1a1
2/2 n=18), 18 weeks (WT n=10,
Aldh1a1
2/2 n=10), 26 weeks (WT n=10, Aldh1a1
2/2 n=9), and
36 weeks (WT n=4, Aldh1a1
2/2 n=4). Bones were scanned at an
energy level of 55 kVp and intensity of 145 mA. Trabecular bone
volume fraction and microarchitecture were evaluated starting
approximately at 0.6 mm proximal to the distal femoral growth
plate and extending proximally 1.5 mm. Measurements included
bone volume/total volume (BV/TV), trabecular number (Tb.N.),
trabecular thickness (Tb.Th.), and trabecular spacing. Scans for
the cortical region were measured at the midpoint of each femur,
with an isotropic pixel size of 21 mm and slice thickness of 21 mm,
and used to calculate the average BA, total cross-sectional area,
BA/total cross-sectional area, and Ct.Th. All scans were analyzed
using manufacturer software (version 4.05; Scanco Medical AG).
Histomorphometry
Twelve week-old female WT (n=5) and Aldh1a1
2/2 (n=5)
mice were subcutaneously injected with 20 mg/kg calcein and
40 mg/kg demeclocycline on days 7 and 2 before necropsy,
respectively. Tibias were removed and embedded without
demineralization in methyl methacrylate. Undecalcified sections
were cut at a thickness of 5 mm and mounted unstained for
dynamic measurements (i.e., mineral apposition rate [MAR],
mineralizing surface (MS/BS) and bone formation rate expressed
per bone surface [BFR/BS], bone volume [BFR/BV], and tissue
volume referent [BFR/TV]). Consecutive sections were stained
with toluidine blue and TRAP to quantify osteoblast number and
osteoclast number, respectively. Adipocyte number was counted
using toluidine blue–stained sections. Histomorphometric analysis
was performed using the OsteoMeasure system (Osteometrics
Inc.), and the results were expressed according to standardized
nomenclature [30].
Bone Marrow Cell Isolation
Bone marrow stromal cells were isolated as previously described
[31]. Briefly, tissue was dissected away from femurs and tibiae of
age and sex matched WT and Aldh1a1
2/2 mice. Bone marrow
was then flushed from the bones with aMEM media (Life
Technologies) supplemented with 10% lot-selected Hyclone fetal
bovine serum (FBS) (VWR International) and 1% penicillin-
streptomycin (Life Technologies). Cells were then strained with
70 mM filter and then seeded for CFU-F, differentiation, and
retinoid cellular assays as outlined below.
Colony Forming Unit-Fibroblast (CFU-F) Assay
Bone marrow cells were isolated from WT and Aldh1a1
2/2
mice and plated at a density of 1610
6 cells/cm
2. Cells were
cultured in basal media consisting of aMEM media (Life
Technologies) supplemented with 10% Hyclone fetal bovine
serum (VWR International) and 1% penicillin-streptomycin (Life
Retinaldhehyde Dehydrogenase 1 Deficiency and Bone
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enumerate CFU-F [32]. For quantitative CFU-F assays, primary
WT and Aldh1a1
2/2 marrow cells were plated in 96 well dishes
(10
5 cells/well) and cultured in basal media for 14 days. Crystal
violet staining was performed on day 14, and a well was
considered positive for CFU-F if it contained greater than 20
crystal violet stained cells.
Retinoid Treatment of MSCs
For the retinoid stimulation studies, WT primary marrow
stromal cells were plated at a density of 1610
6 cell/cm
2 in 12 well
dishes and cultured in basal media for 10–14 days till confluence
and then treated for 24 hours with the following: (1) DMSO
(control); (2) Rald (Sigma) at concentrations of 100 nM, 500 nM,
and 1 mM; (3) ATRA (Sigma) across a concentration range of
100 nM, 500 nM, and 1 mM; (4) Diethylaminobenzaldehyde
(DEAB, Sigma) at a concentration of 1 mM; (5) Rald (1 mM)
and DEAB (1 mM); (6) AGN 193109 (Sigma) at a concentration of
1 mM); (7) AGN (1 mM) and Rald (1 mM); (8) HX531 (a kind gift
from Dr. Hiroyuki Kagechika, University of Tokyo, Japan) at a
concentration of 1 mM; and (9) HX531 (1 mM) and Rald (1 mM).
At the conclusion of the 24 hour treatment, RNA was isolated
from the cells as described below (see ‘‘Reverse Transcriptase PCR
and quantitative PCR’’ section below). All stimulations were
performed in triplicate, and validated in a total of 3 independent
experiments.
In vitro MSC Osteoblastogenesis Differentiation
In vitro osteoblastogenesis assays were performed by plating
marrow stromal cells isolated as described above at a density of
10610
6 cell/well in 6 well dishes (1610
6 cells/cm
2). The cells
were grown in basal media for 7 days, and then osteogenic media
(basal media supplemented with ascorbic acid at 50 mg/mL and
beta-glycerol phosphate at 10 mM) for another 7–14 days.
Alkaline phosphatase (ALP) staining (Sigma 86R-KT) and
measurement of ALP activity (Bioassay Systems, DALP-250) were
performed after 7 days of culture in osteogenic media. After
14 days of culture in osteogenic media, alizarin red staining [33]
and calcium content measurements (Bioassay Systems, DALP-250)
were performed. Differentiation assays were performed in
triplicate, and validated in a total of 3 independent experiments.
In vitro MSC Adipogenesis Differentiation
Marrow cells were seeded in 24 well dishes (1610
6 cells/cm
2)
and treated with adipogenesis induction media (basal media
supplemented with rosiglitazone 1 mM [Cayman Chemicals],
insulin 10 mg/mL [Sigma Aldrich], dexamethasone 1 nM [Sigma
Aldrich], and IBMX 0.5 mM [Sigma Aldrich]) on day 10 for 48
hours followed by adipogenesis maintenance media (basal media
supplemented with rosiglitazone 1 mM, insulin 10 mg/mL) for
5 days. Oil Red O (ORO) staining was performed and quantified
by counting ORO-positive cells in 5 random high power fields per
genotype. Quantification of in vitro adipogenesis was also per-
formed using the AdipoRed Assay (Lonza) according to the
manufacturer’s protocol. Differentiation assays were performed in
triplicate, and validated in a total of 3 independent experiments.
MSC Proliferation
Marrow cells (2610
4 cells/well) were cultured in 96-well plates
and proliferation was measured using BrdU incorporation (Roche
Applied Science) at day 3,7, and 10 of culture according to the
manufacturer’s protocol.
Reverse Transcriptase PCR (RT-PCR) and Quantitative Real
Time PCR (qPCR)
RNA was harvested from cells using Trizol (Life Technolo-
gies). For gene expression analysis in whole bone, RNA was
isolated from one femur and tibia from matched WT controls and
Aldh1a1
2/2 female mice (n=10–12 per genotype) using the
Qiagen TissueLyzer II System according to the manufacturer’s
protocol. RT-PCR was performed with 0.5–1 mg of RNA using
the High Capacity cDNA synthesis kit (Applied Biosystems,
Bedford, MA). Gene expression analysis was performed using an
iQ quantitative real time thermal cycler system (Bio-Rad). One mL
of diluted cDNA (diluted 1:5) generated from RT-PCR was then
used as template for qPCR amplification using 2X iQ SYBR green
mastermix (Bio-Rad) in a total reaction volume of 25 mL. The
delta-delta Ct method (DDCt) was employed in qPCR analysis to
determine relative changes in mRNA expression. The ribosomal
gene 36B4 was used as the internal control gene.
Western Blot
Cell lysates were collected using RIPA buffer (Boston Biopro-
ducts Inc). For whole bone samples, femur and tibias were
dissected and immediately flash frozen in liquid nitrogen (n=4 per
genotype). The frozen bone samples were then crushed using a
BioPulverizer (Biospec Products) and the fragments were then
homogenized in RIPA buffer using the TissueLyzer system
(Qiagen). Western blot analysis was carried out as described [34]
using Aldh1a1 (AbCam), GAPDH (Santa Cruz Biotechnology),
Phospho-Smad1–5–8, Smad 1, beta-actin (Cell Signaling Tech-
nologies) antibodies.
Statistical Analysis
All data are presented as means 6 standard deviations.
Unpaired student t-tests were employed in the statistical analysis
of WT and Aldh1a1
2/2 skeletal phenotyping data (PIXImus
densitometry, mCT, histomorphometry), and in vitro assays (CFU-F
Giemsa quantification, ALP activity, calcium measurements,
Adipored assay for quantification of adipogenesis, and gene
transcript expression analysis). For the retinoid treatments of WT
marrow stromal cultures, a two way ANOVA statistical method
was used in the analysis of differences between BMP2 mRNA
expression in samples treated with DMSO versus retinoids and
retinoid receptor modulators (see above). Post hoc analysis for
significance of difference between the means of each treatment
group was performed using the Tukey multiple comparisons test.
Results
Aldh1a1 is the Predominant Aldh isoform Expressed in
Bone in vivo
Given the existence of three Aldh1 isoforms, we examined
expression of Aldh1a1, 2 and 3 mRNA levels in whole bone.
Aldh1a1 was the primary Aldh isoform expressed in the femurs
and tibias of WT female mice (Figure 1A). As expected, Aldh1a1
protein was present in the long bones of WT but not Aldh1a1
2/2
mice (Figure 1B). We then examined Aldh1a1 expression patterns
during in vitro MSC osteoblastogenesis and adipogenesis. Aldh1a1
is expressed at low levels in primary WT MSCs derived from
12 week old mice but is induced during differentiation of MSCs
into osteoblast (Figure 1C) and adipocyte lineages in vitro
(Figure 1D).
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To test the hypothesis that Aldh1a1 functions as a determinant
of bone mineral density, we performed skeletal phenotyping of age
and sex-matched WT C57Bl6 and Aldh1a1
2/2 mice at multiple
time points (8, 12, 18, 26, 36 weeks). Dual x-ray absorptive
densitometry (DEXA) demonstrated that Aldh1a1
2/2 female mice
had higher total femoral bone mineral density (BMD) and bone
mineral content (BMC) than age-matched WT controls
(Figure 2A). As early as 12 weeks of age, Aldh1a1
2/2 mice had
statistically significant increases in total femoral BMD
(0.064360.0076 vs. 0.052660.0013, p=8.82610
26) and BMC
(0.28160.0026 vs. 0.21860.0020, p=1.75610
29). These patterns
persisted through 36 weeks of age. Aldh1a1
2/2 mice exhibited a
similar pattern on micro computed tomography (mCT) (Figure 2A).
Compared to WT controls, Aldh1a1
2/2 mice had increased
trabecular and cortical bone mass as well as micro-architectural
changes suggestive of increased osteoblastic activity in vivo
(Figure 2B and Table S1 and S2). By 12 weeks of age,
Aldh1a1
2/2 mice demonstrated significant increases in femoral
trabecular bone volume/total volume (BV/TV; 0.092960.0240
vs. 0.034960.0128, p=1.42610
29), femoral cortical BV/TV
(0.56760.023 vs. 0.45460.0171, p=5.23610
28), and cortical
thickness (0.24760.0157 vs. 0.19560.0104 mM, p=3.76610
26).
These findings were accompanied by increases in trabecular
number (TbN; 4.66160.604 vs. 3.21760.158, p=0.0046) and a
lower structure model index (SMI; 2.74560.203 vs. 3.54860.321,
p=0.035) as early as 8 weeks of age.
To evaluate bone remodeling, static and dynamic histomor-
phometric analysis was performed on 12 week-old female WT and
Aldh1a1
2/2 mice (Figure 3 and Table 1). Consistent with the non-
invasive phenotyping studies above, Aldh1a1
2/2 mice manifest
greater cortical thickness (242610 vs 203612 mm, p=0.041), as
well as a trend toward higher osteoid surface per bone surface
(22.7762.91 vs. 19.8062.58%, p=0.451) (Figure 2A). In addi-
tion, Aldh1a1
2/2 mice exhibited a trend toward higher osteoblast
numbers as seen on number of osteoblasts per bone perimeter
(NOb/B.Pm; 27.7963.32 vs. 22.7261.43/mm, p=0.199) and
bone formation rate (21696112 vs. 18386138%/year,
p=0.0997) (Figure 3A). Interestingly, histological sections from
Aldh1a1
2/2 mice revealed significantly higher total adipocyte
numbers (NAd/TAr) versus WT controls (70.74648.72 vs.
12.6466.66, p=0.0296) while adipocyte diameter was unchanged
(Figure 3B). Given these findings, we then examined serum
markers of osteoblast function and bone turnover in age and sex-
matched WT and Aldh1a1
2/2 mice (Table 2). Among the markers
assayed, Aldh1a1
2/2 mice demonstrated the most consistent
differences in serum insulin-like growth factor one (IGF-1), which
has previously been reported as an important determinant of bone
development and growth [35–37]. Aldh1a1
2/2 mice had statisti-
cally significant increases in serum IGF-1 levels at 12 and 36 weeks
and clear trends toward higher serum IGF-1 levels at 18 and 26
weeks of age. Serum osteocalcin (OCN) was not significantly
different at multiple developmental time points. Serum Trap5B
was higher only in 26 week-old Aldh1a1
2/2 mice compared to WT
controls, but was not elevated at 12, 18, or 36 weeks of age. We
also measured serum C-terminal telopeptides of type 1 collagen, a
marker of bone resorption, (RatLaps
Tm, KeraFast) in 18 week-old
WT and Aldh1a1
2/2 mice, and found no significant differences
(data not shown).
Aldh1a1 Deficiency Increases MSC Osteoblastogenesis
and Adipogenesis in vitro
Given the results of the phenotyping studies and histomorpho-
metric analysis, we sought to determine whether Aldh1a1
deficiency modulated fundamental aspects of bone marrow MSC
function and differentiation. To do this, we performed in vitro
CFU-F assays, which provide a measure of MSCs within the bone
marrow niche. Primary marrow stromal cultures from Aldh1a1
2/2
mice formed more CFU-F as compared to WT as quantified by
crystal violet staining and CFU-F enumeration by Giemsa staining
and microscopy (Figure 4A). To exclude that this increase in CFU-
Figure 1. Aldh1a1 expression in bone. A. Quantitative real time PCR revealed Aldh1a1 as the predominant Aldh1 isoform expressed in the long
bones (femur and tibia) of WT mice. B. Western blot analysis of whole bone from WT and Aldh1a1
2/2mice (n=4 per genotype). No Aldh1a1 was
detectable in femurs and tibias of Aldh1a1
2/2mice. C. Aldh1a1 expression during primary MSC osteoblastogenesis. Aldh1a1, along with the
osteoblast marker alkaline phosphatase (ALP), are induced during in vitro MSC differentiation into osteoblast (OB) lineage. D. Aldh1a1 expression
during primary MSC adipogenesis. Aldh1a1 and aP2, a marker of mature adipocytes, are induced during in vitro MSC differentiation into an adipocyte
(Ad) lineage. *p,0.05.
doi:10.1371/journal.pone.0071307.g001
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studies were undertaken, and these assays revealed no difference in
proliferation between WT and Aldh1a1
2/2 cultures (Figure 4A).
We then examined the effect of Aldh1a1 deficiency on MSC
differentiation by conducting in vitro MSC osteoblastogenesis and
adipogenesis assays using primary marrow stromal cultures
(Figure 4B, C). Aldh1a1
2/2 primary marrow stromal cultures
treated with ascorbic acid (50 mg/mL) and beta-glycerol phos-
phate (10 mM) demonstrated enhanced MSC osteoblastogenesis
as measured by alkaline phosphatase staining and activity
(40.34615.57 vs. 4.3860.73 IU/L, p=0.016) after 7 days of
differentiation (Figure 4B). In addition, Aldh1a1
2/2 osteoblasto-
genesis cultures displayed greater mineralization by alizarin red
staining and calcium content (536.06151.20 vs.
50.94642.81 mg/dL/mg of protein, p=0.0059) after 14 days of
differentiation. Consistent with these findings, Aldh1a1
2/2 osteo-
blastogenesis cultures expressed higher levels of key osteogenic
transcription factors and signaling proteins, including Runx2, Osx,
wingless-type MMTV integration site family member 10b
(Wnt10b), as well as OCN, a marker of mature osteoblasts.
Given the observed increase in bone marrow adiposity in vivo in
Aldh1a1
2/2 mice, we next studied in vitro MSC adipogenesis as a
Figure 2. Aldh1a1 deficiency increases trabecular and cortical bone density by bone densitometry and micro CT (mCT). A. Total
femoral bone mineral density (g/cm
2) and bone mineral content (g) by DEXA (PIXImus) of age and sex-matched WT and Aldh1a1
2/2 female mice on
standard chow diet at multiple time points including 8 weeks (WT n=5, Aldh1a1
2/2 n=5), 12 weeks (WT n=20, Aldh1a1
2/2 n=18), 18 weeks (WT
n=10, Aldh1a1
2/2 n=10), 26 weeks (WT n=10, Aldh1a1
2/2 n=9), and 36 weeks (WT n=4, Aldh1a1
2/2 n=4), B. mCT of 12 week-old female WT and
Aldh1a1
2/2 mice on standard chow diet demonstrated a significant increase in femoral trabeculations and cortical density (top left panels). mCT was
performed at 6 weeks (WT n=5, Aldh1a1
2/2 n=5), 8 weeks (WT n=5, Aldh1a1
2/2 n=5), 12 weeks (WT n=20, Aldh1a1
2/2 n=18), 18 weeks (WT
n=10, Aldh1a1
2/2 n=10), 26 weeks (WT n=10, Aldh1a1
2/2 n=9), and 36 weeks (WT n=4, Aldh1a1
2/2 n=4). These studies demonstrated these
differences arise as early as 6–8 weeks of age and persist through 36 weeks of age. *p,0.05.
doi:10.1371/journal.pone.0071307.g002
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2/2 marrow stromal
cultures treated with a standard adipogenic cocktail (insulin,
dexamethasone, IBMX, rosiglitazone) formed more adipocytes by
ORO staining. In addition, Aldh1a1
2/2 marrow adipogenesis
cultures accumulated more intracellular neutral lipids than WT
controls by quantification of AdipoRed staining using absorbance
measurements (330.17666.2 vs. 141.08621.12, p=0.0080)
(Figure 4C). Mature adipocyte phenotypic markers such as fatty
acid binding protein 4 (aP2) and CD36 expression were also
induced significantly more in the primary Aldh1a1
2/2 adipogen-
esis cultures.
Aldh1a1 Deficiency Induces BMP2 in Primary MSCs and in
the Skeleton in vivo
To investigate molecular mechanisms involved in the concom-
itant increase in both osteoblastogenic and adipogenic Aldh1a1
2/2
MSCs, we examined mRNA expression patterns of key proteins
and transcription factors involved in MSC lineage determination
(Figure 5A). Compared to WT controls, undifferentiated primary
Aldh1a1
2/2 marrow stromal cultures selectively expressed signif-
icantly higher levels of BMP2 (p=0.021) in the marrow
microenvironment. BMP2 plays an essential role in bone
formation primarily through Smad and p-38/MAP signaling
pathways [21,38]. BMP2 can also promote MSC adipogenesis
in vitro through Smad-dependent mechanisms [23,38]. This
approximately two-fold increase in BMP2 mRNA expression in
Aldh1a1
2/2 marrow stromal cultures was accompanied by higher
expression of several downstream targets of BMP2, including
Runx2, Dlx3, and Dlx5. The expression of other BMPs implicated
in MSC differentiation, such as BMP4 and 7 as well as BMP
receptors (BMPRIA, BMPR1B, BMPRII), was not significantly
different between WT and Aldh1a1
2/2 MSCs (data not shown).
Other transcription factors that modulate MSC adipogenesis
specifically, such as PPARc1, PPARc2 (Figure 5A) and C/EBPs
(data not shown), were not differentially expressed in Aldh1a1
2/2
marrow stromal cultures.
To determine whether similar gene expression patterns were
present in the skeleton of Aldh1a1
2/2 mice in vivo, mRNA
transcript analysis was performed on RNA isolated from whole
bone (femurs and tibias) from matched, chow-fed WT and
Aldh1a1
2/2 mice. BMP2 expression was approximately three fold
higher in the long bones of the Aldh1a1
2/2 mice (p=0.0440)
versus WT controls (Figure 5B). Osteogenic downstream targets of
BMP2-Smad pathways, including Runx2 and ALP, were also
Figure 3. Histomorphometry of Aldh1a1
2/2mice demonstrates increased cortical bone density. A. Static histomorphometry
demonstrated significant increases in cortical thickness in 12 week old Aldh1a1
2/2 mice (n=5) compared to WT controls (n=5). There were no
significant differences in trabecular microarchitecture and bone density; however, a trend toward higher osteoid surface to total surface area (OS/OV)
and bone formation rate per bone volume (BFR/BV) on dynamic histomorphometry was noted. B. Marrow adipocyte content of Aldh1a1
2/2mice.
Toluidine blue staining (top panels) and adipocyte ghost quantification demonstrated higher marrow adipocyte content in Aldh1a1
2/2 mice
compared to WT controls. The average adipocyte diameter was not significantly different between WT and Aldh1a1
2/2mice. *p,0.05.
doi:10.1371/journal.pone.0071307.g003
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2/2 mice.
BMP2 signaling is known to promote Smad phosphorylation [38].
To assess whether the increased BMP2 mRNA expression seen
here was accompanied by functional distal signaling changes,
western blotting was performed to determine Smad phosphoryla-
tion status (Figure 5C). Phosphorylated Smad 1–5–8 proteins to
total Smad 1 protein ratios were significantly increased in femurs
and tibias of Aldh1a1
2/2 mice as seen on densitometry (1.7360.34
vs. 1.0960.40; p=0.048). Since Aldh1a1 controls the levels of key
retinoid metabolites that modulate retinoid receptor activity, we
also examined skeletal expression of a cassette of retinoid-regulated
genes. Cyclin-dependent kinase inhibitor 1a (Cdkn1), a canonical
retinoid-regulated target gene [39,40] with a retinoic acid response
element in its promoter [41], is expressed at higher levels in the
femurs and tibias of Aldh1a1
2/2 mice compared to controls
(Figure S1A). In addition, the retinoid-regulated genes transglu-
taminase 2 (Tgm2) [42] and osteopontin (OPN) [43] were also
significantly induced in the long bones of Aldh1a1
2/2 mice. Other
retinoid target genes, including uncoupling protein 1 (UCP-1) [44]
and retinoic acid receptor beta (RARb) [43] trended toward
increased levels as well (Figure S1A). In aggregate, these data
suggest that Aldh1a1 deficiency enforced a fundamental shift in
retinoid signaling in bone in vivo.
Given that Aldh1a1 converts Rald to ATRA specifically, we
next tested the effects of Rald stimulation on WT MSCs to further
examine potential mechanisms involved in induction of BMP2
expression by Aldh1a1 deficiency. Primary WT marrow stromal
cultures stimulated with Rald at concentrations of 100 nM,
500 nM, and 1 mM for 24 hours (Figure 5D) expressed
significantly higher BMP2 mRNA levels compared to DMSO-
treated cultures (statistically significant based on a two way
ANOVA test and post hoc analysis with Tukey multiple
comparison test with alpha,0.05). ATRA increased BMP2
expression to a similar extent as Rald at doses of 500 nM and
1 mM. At the lower concentration of 100 nM, ATRA was more
potent than Rald (Figure S1B). To determine whether Rald
exerted its effects on BMP2 expression independent of its
conversion to ATRA, we then co-treated WT marrow stromal
cultures with Rald (100 nM, 500 nM, and 1 mM) and the Aldh1
inhibitor diethylaminobenzaldehyde (DEAB) [44], which blocks
the generation of ATRA from Rald (Figure 5D). Interestingly,
Rald retained its transcriptional effects on BMP2 expression even
in the presence of the Aldh1 inhibitor DEAB (1 mM). To further
investigate whether Rald effects on BMP2 were dependent on
RAR or the retinoid x receptor (RXR), Rald stimulations were
repeated in the presence of the pan RAR-antagonist AGN 193109
(AGN) [45] or the RXR antagonist HX531 [46]. The pan RAR-
antagonist AGN significantly attenuated Rald induction of BMP2
while the RXR antagonist HX531 had no effect (Figure 5E). In
aggregate, these data suggest that Rald stimulates BMP2
expression in MSCs in a RAR-dependent manner, independent
of ATRA formation.
Discussion
Retinoids exert complex, important post-natal skeletal effects.
Recent data has shown that Rald has distinct transcriptional
effects independent of its conversion to ATRA [27]. Thus, the
enzymatic machinery controling levels of Rald, ATRA, and other
retinoid metabolites, is poised to regulate fundamental aspects of
osteogenic programs. Here we demonstrate that Aldh1a1, the
primary enzyme responsible for converting Rald to ATRA in adult
animals, plays an important role in bone metabolism. Non-
invasive imaging with PIXImus and mCT revealed that Aldh1a1
2/
2 mice have higher femoral bone mineral density at multiple
developmental time points. Although mCT identified significant
trabecular and cortical microarchitectural changes in Aldh1a1
2/2
mice (Figure 1), histomorphometry uncovered predominant
increases in cortical thickness only (Figure 2). Thus, Aldh1a1
may play a unique role in cortical bone as a result of local factors
determining enzymatic activity, retinoid levels, or the action of
retinoid-modulated nuclear receptors.
Interestingly, the consistent increase in cortical bone mass
observed in Aldh1a1
2/2 mice across imaging modalities was
coupled to higher bone marrow adiposity. These data suggest that
Aldh1a1 deficiency alters differentiation programs in MSCs, the
common progenitor of osteoblasts and adipocytes in the marrow.
Primary Aldh1a1
2/2 MSCs in marrow stromal cultures manifest
higher BMP2 mRNA expression and enhanced osteoblastogenic
and adipogenic differentiation as compared to WT primary MSCs
(Figure 4). BMP2 was originally described as a potent osteo-
inductive factor [20,21]. Unlike other signaling proteins and
transcription factors such as Taz, PPARc, and Wnts that modulate
MSC lineage determination in a reciprocal fashion, BMP2 may
stimulate both osteoblastogenesis and adipogenesis in MSCs [38].
As such, BMP2 is an appealing candidate for coordinating both
MSC osteoblastogenesis and adipogenesis responses seen in vitro
and in vivo in Aldh1a1 deficiency.
BMP2 signals through Smad transcription factors that are
phosphorylated and activated by the BMP receptor II. Long bones
of Aldh1a1
2/2 mice had higher expression of BMP2 and its
downstream targets, such as Runx2 and ALP, as well as increased
Smad 1–5–8 phosphorylation in vivo (Figure 5). Although Aldh1a1
has various reported functions, its primary biologic role is
conversion of Rald to ATRA, as supported by the higher Rald
levels found in Aldh1a1
2/2 mice [28,34]. Rald potently induced
Table 1. Static and Dynamic Histomorphometeric analysis of
12 week-old WT control and Aldh1a1
2/2 mice.
Parameters WT (n=5) Aldh1a1
2/2 (n=5) p value
BV/TV (%) 5.6160.66 4.0961.00 0.239
Tb.Th (mm) 32.8461.67 28.0361.82 0.087
Tb.N (/mm) 1.7060.13 1.4160.24 0.330
MS/BS (%) 37.7262.60 33.9261.86 0.269
Tb.Sp (mm) 571646 748699 0.143
MAR (mm/day) 2.2160.18 2.4760.19 0.340
BFR/BS (mm
3/mm
2/year) 303627 307635 0.918
BFR/BV (%/year) 104615 93629 0.748
BFR/TV (%/year) 18386138 21696112 0.0997
Ob.S/BS (%) 28.1062.95 29.5061.79 0.695
N.Ob/T.Ar (/mm
2) 66.4364.79 65.7967.49 0.944
N.Ob/B.Pm (/mm) 22.7261.43 27.7963.32 0.199
OV/TV (%) 0.20460.021 0.19760.029 0.850
OS/BS (%) 19.8062.58 22.7762.91 0.466
O.Th (mm) 3.8060.17 3.8560.32 0.888
Oc.S/BS (%) 2.3760.39 1.7560.55 0.389
N.Oc/T.Ar (/mm
2) 2.6360.37 1.7960.64 0.290
N.Oc/B.Pm (/mm) 0.8960.11 0.6660.22 0.385
ES/BS (%) 0.9860.31 0.3860.25 0.172
Cortical thickness (mm) 203612 242610 0.041
doi:10.1371/journal.pone.0071307.t001
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(Figure 5), consistent with the possibility that Rald drives the
changes in bone in Aldh1a1 deficiency. Based on the data
presented here, Rald appears to induce BMP2 through direct
RAR-dependent transcriptional actions (Figure 5F). A well-
established RAR antagonist (AGN) completely blocked Rald-
mediated induction of BMP2 expression in MSCs while an RXR
antagonist (HX531) had no such effect, suggesting nuclear
receptor selectivity. Previous work indicates that RAR may
modulate key transcriptional events at the BMP2 promoter in
F9 embryonal cells [47]. In this cellular context, RAR forms a co-
regulatory complex with SP1 at the BMP2 promoter that represses
Figure 4. Primary Aldh1a1
2/2 MSCs demonstrate enhanced osteoblastogenesis and adipogenesis in vitro. A. Colony forming unit-
fibroblast (CFU-F) assays. Aldh1a1
2/2 marrow stromal cultures form more CFU-F by crystal violet staining and enumeration of Giemsa stained colonies
after 7 days. Brdu incorporation assays showed no significant differences in proliferation between WT and Aldh1a1
2/2 cultures. B. In vitro MSC
osteoblastogenesis differentiation assays. Primary Aldh1a1
2/2 marrow stromal cultures treated with ascorbic acid (25 mg/mL) and beta-glycerol
phosphate (0.1 M) for 7 days expressed more alkaline phosphatase (ALP) as measured by histological staining and ALP activity assays compared to
WT cultures. At 14 days, Aldh1a1
2/2 osteogenic cultures also demonstrated greater mineralization by alizarin red (AR) staining and calcium
measurements. Gene expression analysis after 7 days of osteoblast differentiation showed higher expression of Runx2, Osx, Dlx 3, Dlx 5, Wnt 10b, and
OCN in Aldh1a1
2/2 cultures. C. In vitro MSC adipogenesis differentiation assays. Adherent primary Aldh1a1
2/2 marrow stromal cells induced to
undergo adipogenesis formed more oil red O (ORO) positive cells and accumulated more intracellular lipid than WT controls. Gene transcript analysis
showed corresponding increases in adipogenic markers such as aP2 and CD36. For all the cellular assays, each experiment was performed with
experimental triplicates and repeated a minimum of 3 times. The data presented are from 1 representative experiment. *p,0.05.
doi:10.1371/journal.pone.0071307.g004
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PLOS ONE | www.plosone.org 8 August 2013 | Volume 8 | Issue 8 | e71307Figure 5. Aldh1a1 deficiency induces BMP2 expression in bone cells in vitro and in vivo. A. Gene expression analysis of primary Aldh1a1
2/
2 marrow stromal cultures. Aldh1a1
2/2 marrow stromal cultures express higher levels of BMP2 in vitro. B. BMP2 expression in long bones (femur and
tibia). BMP2 mRNA was expressed at higher levels in the long bones of Aldh1a1
2/2 mice (n=10) compared to WT (n=8). In addition, downstream
transcriptional targets of BMP2 activated Smad proteins such as Runx2 and ALP are also induced in bones from Aldh1a1
2/2 mice compared to WT
controls. C. Smad phosphorylation in long bones of Aldh1a1
2/2 mice. Smad 1,5,8 proteins were phosphorylated to a greater extent in the long bones
of Aldh1a1
2/2 mice (n=4) compared to WT (n=4) by western blot and densitometry analysis. Phosphorylated Smad protein levels were normalized
to total Smad 1 levels. D. Rald effects on BMP2 expression in primary marrow stromal cultures. Rald induced BMP2 expression in WT primary marrow
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dissociates from the promoter, thereby de-repressing BMP2
expression. Although these prior findings and our present data
suggest that Rald accumulation in Aldh1a1 deficiency may
modulate BMP2 promoter activity in MSCs through similar
mechanisms, the bone phenotype in Aldh1a1 deficiency raises the
possibility of other levels of potential control through Rald and/or
Aldh1a1– a topic of considerable interest for future studies.
In examining factors responsible for increased cortical bone
density in Aldh1a1
2/2 mice, we considered differences in lean
mass, which correlates with cortical thickness [48–51]. However,
chow-fed matched WT and Aldh1a1
2/2 female mice have similar
total body weights, fat mass, and lean mass [52]. Another potential
contributor to the cortical bone phenotype of the Aldh1a1
2/2 mice
is serum IGF-1, which has also been implicated in selective
increases in cortical thickness through modulation of periosteal
apposition during growth [53]. Indeed, Aldh1a1
2/2 mice manifest
higher serum IGF-1 levels at 12 and 36 weeks of age (Table 2),
suggesting that the cortical bone phenotype of Aldh1a1
2/2mice
may, at least in part, be the result of higher levels of IGF-1.
Aldh1a1 deficiency may also shed light on age-related bone loss.
Cortical thinning is a key feature of human Type II osteoporosis
[54,55], as well as age-related bone loss in murine models [56].
Female C57Bl/6 mice lose significant cortical bone as early as 7
months of age [57]. Aldh1a1
2/2mice, which have significantly
higher cortical bone thickness and cortical BV/TV by mCT as
early as 6 weeks of age, appear to resist age-related bone loss
through at least 36 weeks of age (Figure 1). Aldh1a1 deficiency
may promote this phenotype through multiple mechanisms.
Higher serum IGF-1 levels in Aldh1a1
2/2 mice may confer
protection against age-related cortical bone loss through selective
effects on cortical periosteal apposition growth. In addition,
osteoblast insufficiency has been strongly implicated as a major
factor in age-related bone loss [58]. Our data indicate that
Aldh1a1 deficiency drives enhanced osteoblast activity and
mineralization. Finally, given that bone resorption is increased in
osteoporosis [59], the higher cortical thickness in Aldh1a1
2/2 mice
could result from osteoclast effects. Although similar osteoclast
numbers and serum markers of bone turnover such as Trap5B and
RatLaps were observed in matched WT and Aldh1a1
2/2 mice, a
trend toward a lower eroded surface/bone surface (0.9860.31%
vs. 0.3860.25%, p=0.17; Table 2) raises the possibility that a
functional osteoclast defect may contribute to the cortical bone
phenotype in Aldh1a1 deficiency.
Of note, a recent study reported that deficiency of acetaldehyde
dehydrogenase, which oxidizes acetaldehyde during ethanol
metabolism, results in greater cortical bone thickness, with
increased expression of osteogenic genes including BMP2, Runx2,
Osx, and Wnt 5a; changes in bone marrow adiposity were not
noted [60]. Despite the similarity in the skeletal phenotypes in
acetaldehyde dehydrogenase and Aldh1a1 deficiency, limited
overlap exists between the substrates or biological roles of Aldh1a1
and acetaldehyde dehydrogenase. Acetaldehyde dehydrogenase
oxidizes acetaldhehyde but does not bind or metabolize Rald
[61,62]. Although Aldh1a1 can bind acetaldehyde, it does so with
a 50-fold lower affinity than Rald, its primary substrate [63].
Nevertheless, the shared cortical bone phenotypes seen in these
models raise intriguing questions regarding convergent distal
pathways worthy of further study while supporting the notion that
key metabolic enzymes and their substrates may play important,
overlooked roles in determining bone formation.
Consistent with this concept, we provide here in vitro and in vivo
evidence that Aldh1a1 deficiency increases cortical bone density.
These changes appear to result from increased BMP2 expression
and shifts in MSC lineage fate decisions that drive coordinated
changes in bone density and marrow adiposity in Aldh1a1
deficient mice. These results suggest further consideration is
warranted regarding the regulation of Aldh1a1 and Rald in
metabolic disorders like osteoporosis, diabetes, and obesity that are
characterized by changes in both bone density and marrow
adiposity.
Supporting Information
Figure S1 A. Gene expression patterns of retinoid targets in
femurs and tibias of matched WT and Aldh1a1
2/2 mice.
Aldh1a1
2/2 mice express higher levels of the retinoid target
cdkn1a in their femurs and tibias compared to WT. B. Effects of
ATRA on BMP2 expression in primary WT marrow stromal
cultures. ATRA induced BMP2 expression in WT primary
marrow stromal cultures after 24 hours of treatment at
concentrations of 100 nM, 500 nM, and 1 mM. * p,0.05.
(TIF)
Table S1
(DOCX)
stromal cultures after 24 hours of treatment at concentrations of 100 nM, 500 nM, and 1 mM. Rald-mediated induction of BMP2 in WT marrow stromal
cultures was not blocked by the Aldh1 inhibitor DEAB (1 mM). E. The RAR antagonist AGN (1 mM), but not the RXR antagonist HX531 (1 mM),
significantly attenuated Rald-mediated induction of BMP2. The data presented are from one representative experiment. The studies were performed
with experimental triplicates and validated in 3 independent experiments. *p,0.05.
doi:10.1371/journal.pone.0071307.g005
Table 2. Serum Markers.
Serum Marker 12 weeks 18 weeks 26 weeks 36 weeks
IGF-1 (ng/mL) WT: 470.26102.8 (n=22) WT: 488.36121.0 (n=16) WT: 568.7668.8 (n=4) WT: 486.8685.5 (n=4)
Aldh1a1
2/2: 577.56180.7* (n=20) Aldh1a1
2/2 : 597.56206.6 (n=15) Aldh1a1
2/2 : 649.66247.7 (n=9) Aldh1a1
2/2: 779.06139.1* (n=3)
OCN (ng/mL) WT: 63.4656.8 (n=16) WT: 41.3629.1 (n=16) WT: 35.1622.8 (n=4) WT: 16.167.0 (n=4)
Aldh1a1
2/2:4 6 . 5 631.7 (n=15) Aldh1a1
2/2 :4 4 . 1 622.9 (n=16) Aldh1a1
2/2 : 20.4614.4 (n=9) Aldh1a1
2/2: 8.267.5 (n=3)
Trap5B (U/L) WT: 7.461.0 (n=16) WT: 7.362.4 (n=11) WT: 5.160.5 (n=5) WT: 6.561.2 (n=4)
Aldh1a1
2/2 :7 . 9 62.5 (n=16) Aldh1a1
2/2 :1 1 . 1 63.6 (n=11) Aldh1a1
2/2 :7 . 3 61.6* (n=9) Aldh1a1
2/2: 10.865.6 (n=3)
*p,0.05.
doi:10.1371/journal.pone.0071307.t002
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